Quince Therapeutics Says Brigette Roberts Conditionally Appointed As CEO; John Militello Conditionally Appointed As CFO
Quince Therapeutics Inc QNCX
$23.39
▲ +1.56%
(+$0.36)
🗓️ Earnings Next Week
Open
$23.47
Prev Close
$23.03
Day Range
$21.55 – $24.59
52W Range
$15.10 – $910.00
Market Cap
$22.87M
Beta
1.24
EPS (TTM)
$-9.11
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-05-09 |
| Shares Out. | 980,000 |
| Website | quincetx.com/ ↗ |
| Phone | 14159105717 |
| Employees | 38 |
| Net Income | $35.9M |
| Free Cash Flow | -$37.7M |
| Total Assets | $26.6M |
| Total Liabilities | $11.0M |
| Equity | $15.7M |
About Quince Therapeutics Inc
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Quince Therapeutics Inc is a publicly traded company under the ticker symbol QNCX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)